Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
The long-term treatment of metastatic medullary thyroid carcinoma (MTC) with somatostatin (SST) analogs was evaluated in 22 patients with persistant or relapsed disease and with in vivo positive SST receptor (SSTR) tumors. After surgical intervention all patients but one, initially or at a later time, had persistenly (15) or after relapse (7) elevated serum calcitonin (CT, 252-69482 pg/ml) and carcinoembryonic antigen (CEA, 8-1130 ng/ml) concentrations; also, all of them showed positive uptake in 111In-pentetreotide scanning. Daily doses of 0.4-1.0 mg octreotide subcutaneously, or monthly doses of 20-30 mg long-acting octreotide (LAR) intramuscularly for 3-21 months were administered. Systemic chemotherapy (Ch) with or without external radiotherapy (eRT) was given to 13 patients simultaneously. A beneficial effect on pre-existing diarrhea was observed in 8 patients (subjective partial remmission, sPR 36.4%); 10 other patients showed stable disease, while in 4 a worsening of pre-existing diarrhea was observed. CT and CEA concentrations decreased more than 25% in 4 out of 22 patients (18%) and 11 patients showed a decrease of less than 25% (biological SD). No objective response in tumour growth was demonstrated. Patients (10 survivors in group B) treated with Ch+eRT plus Octerotide showed higher sR (92.5%), lower mortality (23.1%), longer mean time to death (130 months) and longer mean total survival (mts) time (145 months) in comparison to group A patients who had 66.7% sR, 33.3% mortality, only 88.5 months mean time to death and 101 months mts-time. Long-term octreotide and octreotide-LAR treatment offers a subjective and biological partial remission in one third and in one fourth of the MTC patients respectively, but it does not improve the natural course of the tumor. It remains to be answered if these drugs, combined with other antineoplastic therapies, have a synergistic effect relating to treatment response and to patient survival and mortality.
Vainas
I
I
Dept. of Endocrinology and Endocrine Oncology, Theagenion Anticancer Hospital of Thessaloniki, Greece.
Koussis
Ch
Ch
Pazaitou-Panayiotou
K
K
Drimonitis
A
A
Chrisoulidou
A
A
Iakovou
I
I
Boudina
M
M
Kaprara
A
A
Maladaki
A
A
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D020295:Brain Stem Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D002116:Calcitonin / Q000097:blood; D002277:Carcinoma / Q000188:drug therapy* / Q000378:metabolism*; D002648:Child; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015282:Octreotide / Q000378:metabolism; D011877:Radionuclide Imaging; D017481:Receptors, Somatostatin / Q000096:biosynthesis*; D012008:Recurrence; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000494:pharmacology; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D013997:Time Factors; D014018:Tissue Distribution; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007205:Indium Radioisotopes; D017481:Receptors, Somatostatin; D013004:Somatostatin; D002116:Calcitonin; C081788:pentetreotide; D015282:Octreotide